Humacyte, Inc. (NASDAQ:HUMA ) Q2 2025 Earnings Call August 11, 2025 8:00 AM ET Company Participants Dale A. Sander - CFO, Chief Corporate Development Officer & Treasurer Laura E.

DEM offers diversified exposure to high-dividend emerging market stocks but is heavily concentrated in financials and China, increasing sector and geopolitical risks. While DEM has outperformed the EEM benchmark since inception, it has lagged behind key competitors over recent years. Distributions and share price have declined in real terms, resulting in significant inflation-adjusted capital loss for long-term investors.

Jim Cramer beaks down why he's keeping an eye on shares of C3.AI.

The CCS sale in 2026 delivers a one-time cash surge to reset the balance sheet. CommScope will use the proceeds to eliminate both debt and preferred equities and still have excess cash available for dividends. Even before the sale is officially completed, leverage and interest costs are improving, supporting strong sale terms.

Recently, Zacks.com users have been paying close attention to Palantir Technologies (PLTR). This makes it worthwhile to examine what the stock has in store.

Recently, Zacks.com users have been paying close attention to Newmont (NEM). This makes it worthwhile to examine what the stock has in store.

Emerson Electric (EMR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks.com users have recently been watching Devon Energy (DVN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Recently, Zacks.com users have been paying close attention to PulteGroup (PHM). This makes it worthwhile to examine what the stock has in store.

AppLovin (APP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

PDD Holdings Inc. Sponsored ADR (PDD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

UiPath (PATH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Uber (UBER) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Alphabet (GOOGL) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Flywire Corporation ("Flywire" or the "Company") (NASDAQ: FLYW) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-04110, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Flywire securities between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities …

NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 2, …

Proto Labs' cash flows have improved in recent quarters, but the sustainability of this is uncertain due to low CapEx and an ongoing mix shift toward lower margin segments. Growth has also strengthened, driven by a surge in CNC revenue from aerospace and defense customers. While Proto Labs' share price has moved significantly higher, the company's valuation is still fairly reasonable, although this is dependent on the company's ability to drive its margins higher.

NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ: WOOF) and certain officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 25-cv-01667, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Petco securities between January 14, 2021 and June 5, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of …